SeqLL (SEQL) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SeqLL Dividend Payout Ratio?

SeqLL's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for SeqLL's Dividend Payout Ratio or its related term are showing as below:

SEQL's Dividend Payout Ratio is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-19), the Dividend Yield % of SeqLL is 0.00%.

SeqLL's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

SeqLL Dividend Payout Ratio Historical Data

The historical data trend for SeqLL's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeqLL Dividend Payout Ratio Chart

SeqLL Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

SeqLL Quarterly Data
	Dec18	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of SeqLL's Dividend Payout Ratio

For the Diagnostics & Research subindustry, SeqLL's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SeqLL's Dividend Payout Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SeqLL's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where SeqLL's Dividend Payout Ratio falls into.

SeqLL Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

SeqLL's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-15.534
	=	N/A

SeqLL's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-3.307
	=	N/A

SeqLL (OTCPK:SEQL) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

SeqLL Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of SeqLL's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

SeqLL (SEQL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SeqLL Inc (OTCPK:SEQL) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Federal Street, Billerica, MA, USA, 01821

Website

http://www.seqll.com

SeqLL Inc is an early commercial-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple omics fields. The company leverages its expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute advancements to scientific research and development by accelerating one's understanding of the molecular mechanisms of disease and fundamental biological processes, It enables researchers to identify and synthesize DNA or RNA strands, irrespective of abundance, in a biological sample and is capable of analyzing billions of molecules in parallel.

Executives

Douglas Patrick Miscoll	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Daniel Robert Jones	officer: President, CEO	317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
David Pfeffer	director	464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally	officer: CHIEF FINANCIAL OFFICER	66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy	officer: CFO, Secretary	166 WINN STREET, WOBURN MA 01801